In conclusion, our systematic review found that TRPV1, TRPA1 and TRPM8 agonists have beneficial effects for patients with neurogenic oropharyngeal dysphagia when compared to placebo interventions. The gene discussed is TRPV1; the disease is Oral-pharyngeal dysphagia.